Dextran + Hypromellose interactions
Checked as Dextran (-1) in this data source.
Full monograph for Dextran + HypromelloseCheck it against another medicine
Medicines
14 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Major | Synergy | Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 3 sources — open the full entry |
| Apixaban | Major | Synergy | Concomitant use of apixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Betrixaban | Major | Synergy | Concomitant use of betrixaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 39 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Major | Synergy | Drugs that can affect hemostasis such as glycoprotein IIb/IIIa inhibitors, thienopyridine antiplatelet agents, unfractionated and low molecular weight… | 3 sources — open the full entry |
| Dalteparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Enoxaparin Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Fondaparinux Sodium | Major | Synergy | Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the… | 7 sources — open the full entry |
| Ibrutinib | Major | Synergy | Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 4 sources — open the full entry |
| Prasugrel Hydrochloride | Major | Synergy | Concomitant use of prasugrel with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents… | 2 sources — open the full entry |
| Ramucirumab | Major | Synergy | Coadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab… | 2 sources — open the full entry |
| Rivaroxaban | Major | Synergy | Concomitant use of rivaroxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation… | 1 sources — open the full entry |
| Icosapent Ethyl | Moderate | Synergy | Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet… | 7 sources — open the full entry |
| Niraparib | Moderate | Synergy | Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. | 2 sources — open the full entry |
| Pentoxifylline | Moderate | Synergy | The use of pentoxifylline has been associated with bleeding and/or prolongation in prothrombin time. Theoretically, the risk of bleeding may be increased by… | 2 sources — open the full entry |
This source documents no food, condition or duplication entries for Dextran + Hypromellose.